{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["zanzalintinib","nivolumab"]],"indication":"locally advanced/inoperable clear cell renal cell carcinoma","name":"EXPLORE-RCC","nct_id":"NCT06794229","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=explore-rcc-nct06794229. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EXPLORE-RCC","arms":[{"description":"All subjects will receive zanzalintinib 100mg orally (PO) once daily plus nivolumab standard of care dosing (i.e., 240mg IV every 2 weeks or 480mg IV every 4 weeks) for a total of 12 weeks, followed by restaging scan/evaluation for surgical operability and an adaptive approach that includes (1) surgical resection if the participant is eligible for surgery (Cohort A), (2) up to 48 weeks total (from Cycle 1 Day 1) of zanzalintinib plus nivolumab if the participant has partial response or stable disease but remains inoperable (Cohort B1), or (3) stopping protocol mandated treatment to receive standard of care systemic therapy and continue follow up per protocol if the participant has disease progression (Cohort B2).","label":"Zanzalintinib (XL092) and Nivolumab","type":"EXPERIMENTAL"}],"collaborators":["Exelixis","University of Texas"],"completion_date":{"date":"2029-06-06","type":"ESTIMATED"},"conditions":["Locally Advanced Renal Cell Carcinoma"],"enrollment":{"count":69,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Zanzalintinib","otherNames":["XL092"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["Opdivo"],"type":"DRUG"}],"last_update":"2026-09-04","lead_sponsor":"Qian Qin","official_title":"A Phase II, Open-label, Single-arm Study of nEoadjuvant Zanzalintinib (XL092) Plus nivoLumab in Patients With lOcally Advanced and/or inopeRable clEar Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis (EXPLORE-RCC)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-06-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective response rate (ORR)","timeFrame":"12 weeks"}],"references":[],"start_date":{"date":"2025-10-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis","url":"https://clinicaltrials.gov/study/NCT06794229"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/explore-rcc-nct06794229"}